Digital therapeutics for ADHD like Lumosity, Meta Quest, and EndeavorRx may provide new ways to manage ADHD symptoms and monitor related health conditions.
/PRNewswire/ Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining.
– FokusRx™ feasibility study demonstrates positive results – – Company plans to initiate Phase 3 trial with FokusRx in ADHD in the second half of 2022 –.
/PRNewswire/ Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining.
Revibe Technologies Promotes Chief Technical Officer, Welcomes Chief Scientific Officer and Financial Controller as Company Develops ADHD Digital Therapeutic
New CSO brings substantial experience in psychological test development, Controller in accounting and auditing for the healthcare industry
News provided by
Share this article
WAKE FOREST, N.C., April 28, 2021 /PRNewswire/
Revibe Technologies today announced the hiring of Dr. Lindsay Ayearst as Chief Scientific Officer, a new position created to facilitate the clinical and regulatory development of the company s upcoming state-of-the-art digital wearable therapeutic device. In addition, Jen Musso, CPA joins the team as Financial Controller. Chris Guidry who has served as Revibe s Director of Technology since 2017 was also promoted to Chief Technical Officer. This restructuring will be crucial to the company as it works towards developing a next-generation Revibe platform as a medical device to assess and treat ADHD.